| Value | ₹9,600 Cr |
|---|
NSE filing, NSE: CGCL. Summary written from the filing by ALFA Finder's alert engine.
Capri Global Capital Ltd: key numbers
- Share price
- ₹230.24
- Market cap
- ₹22,153 Cr
- Revenue (annual)
- ₹4,731 Cr
- Net profit (annual)
- ₹949.1 Cr
- P/E (TTM)
- 16.9×Sector 19.8×
- Promoter holding
- 59.92%+0.00% QoQ
- FII holding
- 13.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Capri Global Capital Ltd
All →Capri Global Capital Debt & Borrowing: ₹285 Cr
Capri Global signed a bipartite agreement with IIDI as registrar for up to USD 30 million secured bonds. The private placement is worth up to ₹285 Crore.
- Value
- ₹285.0 Cr
Capri Global Capital Debt & Borrowing: ₹1.42 Cr
Capri Global paid interest on four listed NCD series ahead of their due dates, totalling Rs.1.42 Crore. The Reg 57 certificate reports no payment changes or delays.
- Value
- ₹1.42 Cr
Capri Global Capital Earnings Call Transcript: Key Takeaways
Strong core performance overshadowed by a significant gold loan delinquency spike driven by product structural shifts. Management maintains aggressive expansion targets despite asset quality headwinds in rural segments.
Capri Global Capital Credit Rating
India Ratings affirmed CGCL's credit rating at IND AA- with Positive outlook. A new Rs. 500 Cr bank loan facility was also assigned the same rating.
Capri Global Capital Debt & Borrowing: ₹2.27 Cr
Capri Global Capital paid Rs. 226.85 lakh interest on its Series 16 NCDs on the due date of October 28, 2026. The payment is in line with the debenture terms.
- Value
- ₹2.27 Cr
Capri Global Capital Investor Presentation: Key Takeaways
Q2FY27 PAT ₹4,183mn (+77% YoY), NII ₹8,125mn (+69%), AUM ₹438,785mn (+62%). Cost-income improved to 41.4%. No explicit numeric guidance.
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr